Induction of Labor



Induction of Labor


Washington C. Hill

Carol J. Harvey



Induction of labor has become one of the most common obstetric interventions in the United States. Moreover, the rate of labor induction has more than doubled from 9.5 percent in 1990 to 22.3 percent in 2005, and currently accounts for approximately 24 percent of infants born between 37 and 41 weeks gestation in the U.S.1 The rate of induction of labor has also increased for preterm gestations. The increased incidence of induction of labor has been attributed to a number of factors, including the availability and widespread use of cervical ripening agents, logistical issues, and an increase in medical and obstetric indications for delivery. Such variables may be particularly applicable for women who have complications or critical illness during pregnancy.

A number of methods to ripen the cervix and to initiate or augment the labor process have been studied. Nonpharmacologic approaches to cervical ripening and labor induction have included herbal compounds, homeopathy, castor oil, hot baths, enemas, sexual intercourse, breast stimulation, acupuncture, and transcutaneous nerve stimulation. Mechanical methods have included cervical dilators (e.g., laminaria, synthetic hygroscopic agents such as Lamicel or Dilapan, single balloon catheters [e.g., Foley], dual balloon catheters [e.g., Atad Ripener Device], and surgical modalities (e.g., membrane stripping and amniotomy). Of these, only mechanical methods have demonstrated efficacy for timely cervical ripening or induction of labor. Surgical methods possess some efficacy in cervical ripening; however, membrane stripping and amniotomy work to efface the cervix over longer periods of time (i.e., days and weeks for membrane stripping), or only in select population groups (i.e., amniotomy in multiparous women). Pharmacologic methods, specifically prostaglandins, are used more often than other methods for cervical ripening and induction of labor due to their high rate of efficacy and ease of use.2 Multiple randomized studies and meta-analyses have evaluated the benefits, risks, complications, and fetal outcomes of the synthetic prostaglandins (PGE1 and PGE2) with or without concomitant oxytocin infusions, providing clinicians more information on their use in clinical practice.2,3,4,5 Although actual or potential risks may be associated with any method of cervical ripening or labor induction, they should be weighed against the potential benefit to the mother and/or the fetus in a specific clinical situation.

A detailed discussion of each modality available for cervical ripening or induction of labor is beyond the scope of this chapter; however, a list of cervical ripening modalities and recommendations on use or avoidance, based on current Cochrane Database Reviews on labor induction and cervical ripening methods, is presented in Table 12-1. A more detailed summary of specific methods of induction of labor can be found in Table 12-2.

Attention is also directed to recent professional organization practice guidelines for evidence-based information regarding cervical ripening or labor induction methods, including the associated risks, benefits, and safety considerations. The Association of Women’s Health, Obstetric and Neonatal Nurses (AWHONN) has published a comprehensive state of the science third edition monograph on cervical ripening and induction and augmentation of labor, and the American College of Obstetricians and Gynecologists (ACOG) has published an updated Practice Bulletin on induction of labor.2,6

Although there are current publications to advance evidence-based practice in induction and augmentation of labor, similar recommendations for its application to high-risk and critically ill patients are absent. Labor induction in such women must be individualized based on the patient’s specific clinical condition, her capacity to respond to physiologic stress, the gestational age of the pregnancy, and the degree of risk discussed with the patient during the informed consent process. To




effectively care for such complex patients, collaboration among clinicians is essential. Care providers require an understanding of normal pregnancy, uterine physiology, the effect of labor on maternal oxygen transport variables, the effect of the patient’s complication and condition on labor, and the potential adverse events of the selected induction mode (e.g., mechanical, surgical, and/or medical).








Table 12.1 Effectiveness of Methods for Cervical Ripening










































Effective methods Mechanical cervical dilators

  • Osmotic dilators

    • Laminaria
    • Lamicel

  • Balloon devices

    • Foley catheter with 30- to 80-mL balloon volume
    • Double balloon device (Atad Ripener Device)

  • Extra-amniotic saline infusion
  Administration of synthetic prostaglandins PGE2, dinoprostone (Cervidil, Prepidil)
  Administration of synthetic PGE1 analog Misoprostol (Cytotec)
Methods that may be effective* Acupuncture  
Herbal supplements Limited data; need prospective trials
Relaxin

  • Four studies, 267 women
  • Role of relaxin is unclear; more studies needed
  • No difference in Cesarean section rates compared to placebo, but more likely to change cervix to “favorable”
Sexual intercourse

  • Only one study of 28 women
  • Impact remains uncertain
Ineffective methods Amniotomy alone  
Corticosteroids  
Castor oil, bath and/or enema

  • Only one trial on castor oil, poor methodology
  • More studies are needed
Homeopathy

  • Only two trials, study quality low
  • Insufficient evidence, more studies needed
*Some data exist to support use of the method, more data are needed from larger studies with appropriate methodology, or data are conflicting.
No data exist, conflicting data exist, or data exist that refute its purported effect.
Adair, C. D. (2000). Nonpharmacologic approaches to cervical priming and labor induction. Clinical Obstetrics And Gynecology, 43, 447–454.
Alfirevic, Z., & Weeks, A. (2006), Oral misoprostol for induction of labour. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD001338. doi: 10.1002/14651858.CD001338.pub2.
Boulvain, M., Kelly, A. J., & Irion, O. (2008). Intracervical prostaglandins for induction of labour. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD006971. doi: 10.1002/14651858.CD006971.
Boulvain, M., Kelly, A. J., Lohse, C., Stan, C. M., & Irion, O. (2001). Mechanical methods for induction of labour. Cochrane Database of Systematic Reviews, Issue 4. Art. No.: CD001233. doi: 10.1002/14651858.CD001233.
Bricker, L., & Luckas, M. (2000). Amniotomy alone for induction of labour. Cochrane Database of Systematic Reviews, Issue 4. Art. No.: CD002862. doi: 10.1002/14651858.CD002862.
French, L. (2001). Oral prostaglandin E2 for induction of labour. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD003098. doi: 10.1002/14651858.CD003098.
Hofmeyr, G. J., & Gulmezoglu, A. M. (2010). Vaginal misoprostol for cervical ripening and induction of labour. Cochrane Database of Systematic Reviews, Issue 10. Art. No.: CD000941. doi: 10.1002/14651858.CD000941.pub2.
Kavanagh, J., Kelly, A. J., & Thomas, J. (2001). Sexual intercourse for cervical ripening and induction of labour. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD003093. doi: 10.1002/14651858.CD003093.
Kavanagh, J., Kelly, A. J., & Thomas, J. (2006). Corticosteroids for cervical ripening and induction of labour. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD003100. doi: 10.1002/14651858.CD003100.pub2.
Kelly, A. J., Kavanagh, J., & Thomas, J. (2001). Castor oil, bath and/or enema for cervical priming and induction of labour. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD003099. doi: 10.1002/14651858.CD003099.
Kelly, A. J., Kavanagh, J., & Thomas, J. (2001). Relaxin for cervical ripening and induction of labour. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD003103. doi: 10.1002/14651858.CD003103.
Luckas, M., & Bricker, L. (2000). Intravenous prostaglandin for induction of labour. Cochrane Database of Systematic Reviews, Issue 4. Art. No.: CD002864. doi: 10.1002/14651858.CD002864.
Smith, C. A. (2003). Homoeopathy for induction of labour. Cochrane Database of Systematic Reviews, Issue 4. Art. No.: CD003399. doi: 10.1002/14651858.CD003399.
Smith, C. A., & Crowther, C. A. (2004). Acupuncture for induction of labour. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD002962. doi: 10.1002/14651858.CD002962.pub2.








Table 12.2 Cochrane Database Reviews on Selective Labor Induction and Cervical Ripening Methods












































Method Study/Outcomes Reviewer Comments
Buccal or sublingual misoprostol (Off-label use) Muzonzini, G., & Hofmeyr, G.J. (2004). Buccal or sublingual misoprostol for cervical ripening and induction of labour. Cochrane Database of Systematic Reviews, Issue 4. Art. No.: CD004221. DOI: 10.1002/14651858.CD004221.pub2
Total trials: Three trials (n = 502)
Buccal or sublingual misoprostol (off-label; route not FDA-approved) compared with vaginal misoprostol (two different doses) and oral misoprostol (two doses)
Buccal misoprostol group had slightly fewer Cesarean sections compared with vaginal misoprostol group. No other differences in outcomes.
Sublingual compared to oral administration of the same dose:
Women in the sublingual misoprostol group were more likely to have a vaginal delivery in 24 hours compared to the vaginal misoprostol group. However, when a smaller dose of misoprostol was studied there were no differences between the two groups.
There are limited data (only three trials) to make conclusions; however, the studies support sublingual misoprostol as being at least as effective as an identical oral dose.
More studies are needed to evaluate the side effects, rates of complications and safety of sublingual or buccal misoprostol before it is used clinically.
Summary point: Neither sublingual nor buccal misoprostol should be used in clinical practice (outside of a registered and approved study) until more data are made available on its overall safety.
Intracervical prostaglandins Boulvain, M., Kelly, A.J., & Irion, O. (2008). Intracervical prostaglandins for induction of labour. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD006971. DOI: 10.1002/14651858.CD006971
Total trials: 56 trials (n = 7,738)
Intracervical PGE2 compared with placebo: 28 trials (n = 3,764)
Women who received intracervical PGE2 were more likely to have a vaginal delivery in 24 hours compared with women in the placebo group.
In a subgroup of women with intact membranes and unfavorable cervices, fewer Cesarean sections were required with PGE2
Although the risk for tachysystole was increased in the intracervical PGE2 group, there was no increased risk for tachysystole with FHR changes in the group.
Intracervical PGE2 compared with intravaginal PGE2: 29 trials (n = 3,881)
More women in the intravaginal PGE2 group had a vaginal delivery within 24 hours compared to women in the intracervical PGE2 group.
There was no difference between the two groups in Cesarean sections or tachysystole with or without FHR changes.
Intracervical PGE2 is more effective compared with a placebo.
However, intravaginal PGE2 is superior to intracervical PGE2.
Summary point: A better alternative than intracervical prostaglandins is intravaginal prostaglandins.
Mifepristone (antiprogestins) (Off-label use) Hapangama, D., & Neilson, J.P. (2009). Mifepristone for induction of labour. Cochrane Database of Systematic Reviews, Issue 3. Art. No.: CD002865. DOI: 10.1002/14651858.CD002865.pub2.
Total trials: 10 trials (n = 1,108)
Mifepristone compared with placebo
Women who received mifepristone were more likely to ripen their cervix and be in labor at 48 hr compared to those who received a placebo. The effect continued to 96 hr.
The mifepristone group was less likely to need augmentation with oxytocin or require a Cesarean section.
Women in the mifepristone group were more likely to have an operative vaginal delivery compared to the placebo group, but were less likely to have a Cesarean section as a result of induction failure.
There were no differences in neonatal outcomes between groups, but there were more abnormal FHR patterns in the mifepristone group.
There is insufficient evidence to support a specific dose. However, 200 mg mifepristone administered as a single dose may be the lowest effective dose for cervical ripening.
Similar to other agents studied for induction of labor, there is insufficient information on the occurrence of uterine rupture or dehiscence in the reviewed studies.
The study findings are of interest due to the evidence that suggests mifepristone is more effective than placebo to prevent induction failure.
There are insufficient data available from clinical trials to support the use of mifepristone to induce labor.
Summary point: There are not enough data to recommend the use of mifepristone at this time. More studies are needed that compare mifepristone with current meds, and that report the effect on the fetus and neonate.
Oral misoprostol (Off-label use) Alfirevic, Z., Weeks A. (2006). Oral misoprostol for induction of labour. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD001338. DOI: 10.1002/14651858.CD001338.pub2.
Total trials: 51
Oral misoprostol compared to placebo: 7 trials (n = 669)
Women administered oral misoprostol were more likely to have vaginal delivery within 24 hr compared to placebo; and had a lower rate of Cesarean section.
Oral misoprostol compared with vaginal dinoprostone: 10 trials (n = 3,368)
Oral misoprostol group less likely to need Cesarean section.
Oral misoprostol may take longer for delivery compared to vaginal dinoprostone, but no other significant differences.
Oral misoprostol compared with intravenous oxytocin: 8 trials (n = 1,026)
No difference between the two groups except for an increase in meconium-stained fluid in the oral misoprostol group in women with ruptured membranes.
Oral misoprostol compared to vaginal PGE2: 26 trials (n = 5,096)
Women who took oral misoprostol compared to IV oxytocin had no differences in maternal and neonatal outcomes or rates of vaginal deliveries. There were fewer neonates with low Apgar scores in the oral misoprostol group compared with vaginal misoprostol. May be due to less uterine tachysystole with and without FHR changes in the oral misoprostol group, but data are difficult to interpret.
Oral misoprostol is an effective induction agent. It is as effective as vaginal misoprostol and results in fewer Cesarean sections than vaginal dinoprostone.
If risk for infection is high, oral misoprostol is preferred over vaginal misoprostol.
Misoprostol remains off-label for induction of labor. Providers may choose to select dinoprostone due to its licensed status.
Summary point: Unlike other drugs for induction and augmentation of labor, oral misoprostol is inexpensive and stable at room temperature. It can be administered orally or vaginally, and the oral route may be safer than giving it vaginally. Oral misoprostol is an effective drug for induction of labor, but the lack of large randomized trials leaves many questions regarding its safety.
Oral prostaglandin E2 (Experimental) French, L. (2001). Oral prostaglandin E2 for induction of labour. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD003098. DOI: 10.1002/14651858.CD003098
Total studies: 19 (15 compared oral or IV oxytocin with or without amniotomy)
Quality of studies was poor. Only seven studies had allocation concealment. Only two studies stated the providers or subjects were blinded to treatment group.
In the composite comparison of oral PGE2 versus all oxytocin treatments (with and without amniotomy), oral PGE2 was slightly more successful for having a vaginal delivery in 24 hr.
There were no clear benefits of oral prostaglandin compared to the other methods for induction.
Oral prostaglandin resulted in more GI complications, including vomiting.
Oral PGE2 resulted in more GI effects (especially vomiting) compared with placebo or oxytocin.
No clear benefit of oral PGE2 compared to other methods of labor induction.
Summary point: Overall, there is little to recommend the use of PGE2 for the induction of labor. Other methods have been shown to be beneficial and effective in induction and augmentation, and most do not produce the significant side effects of nausea, vomiting and diarrhea associated with this drug.
Oxytocin alone Alfirevic, Z., Kelly, A.J., & Dowswell, T. (2009). Intravenous oxytocin alone for cervical ripening and induction of labour. Cochrane Database of Systematic Reviews, Issue 4. Art. No.: CD003246. DOI: 10.1002/14651858.CD003246.pub
Total trials: 61 trials (n = 12,819)
Compared to expectant management, oxytocin increased the likelihood of vaginal birth in 24 hr.
Significant increase in number of women requiring epidural anesthesia.
More women were satisfied with oxytocin as an induction method.
Oxytocin compared with prostaglandins
Compared to prostaglandins, oxytocin decreased the likelihood of vaginal birth in 24 hr (prostaglandins superior to oxytocin alone).
Compared with intracervical prostaglandins
Oxytocin alone likely increased the induction failure rate and the rate of Cesarean sections.
Overall, use of prostaglandins compared to oxytocin alone increases the rate of vaginal birth in 24 hr.
Most studies included women with rupture of membranes; some evidence that vaginal prostaglandins increased infection in mothers and babies; and increased use of antibiotics.
The role of prostaglandins in infection needs further study.
Summary point: Compared to no intervention, oxytocin is an effective agent for induction of labor. However, when oxytocin is compared to some of the prostaglandins, vaginal and intracervical prostaglandins were more effective for labor induction. Additionally, when women who had their labor induced with oxytocin were compared to those that received prostaglandins, the oxytocin group had a higher rate of epidurals.
Relaxin Kelly, A.J., Kavanagh, J. & Thomas, J. (2001) Relaxin for cervical ripening and induction of labour. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD003103. DOI: 10.1002/14651858.CD003103.
Total studies: 4 studies (n = 267)
Cervical ripening and induction:
Relaxin is protein hormone. Role in parturition is unclear. Has been debated since 1950s.
Most studies used relaxin derived from porcine and/or bovine sources; recombinant human relaxin is now available for study.
Thought to promote cervical ripening, but inhibit uterine activity. This may produce less tachysystole.
No reported cases of tachysystole in studies.
No difference in Cesarean section rates compared to placebo.
Cervix more likely to change to favorable.
Role of relaxin in induction and cervical ripening is unclear.
Summary point: More studies are needed.
Vaginal misoprostol (prostaglandin E1 analogue) (Off-label use) Hofmeyr, G.J., Gulmezoglu, A.M., Pileggi, C. (2010) Vaginal misoprostol for cervical ripening and induction of labour. Cochrane Database of Systematic Reviews, Issue 10. Art. No.: CD000941. DOI: 10.1002/14651858.CD000941.pub2
Total trials: 70 trials
Cervical ripening or induction:
Misoprostol more likely to produce vaginal delivery in 24 hr compared to placebo.
Increased uterine tachysystole without FHR changes compared to placebo.
Compared with vaginal prostaglandin E2:
Intracervical prostaglandin E2, and oxytocin, vaginal misoprostol associated with increased likelihood of vaginal delivery, less epidural use, and more tachysystole.
Compared with vaginal E2 or intracervical E2:
Oxytocin augmentation less common with misoprostol; meconium stained amniotic fluid increased with misoprostol.
Higher does of misoprostol associated with more tachysystole (with and without FHR changes), and less need for oxytocin augmentation.
Vaginal misoprostol doses greater than 25 mcg every 4 hr are more effective than lower doses, but more uterine tachysystole.
Studies reviewed are too small to rule out serious but rare events.
Further research needed to identify the ideal dose, route of administration, and to determine if isolated case reports on uterine rupture are related to the drug.
Summary point: The authors conclude that no further studies of vaginal misoprostol are required at this time due to a recent Cochrane review that demonstrated superior performance of oral misoprostol. Further information on the number of significant adverse outcomes such as uterine rupture is needed.
Vaginal prostaglandin (PGE2 and PGF2a) Kelly, A.J., Malik, S., Smith, L., et al. (2009) Vaginal prostaglandin (PGE2 and PGF2a) for induction of labour at term. Cochrane Database of Systematic Reviews, Issue 4. Art. No.: CD003101. DOI: 10.1002/14651858.CD003101.pub2
Total trials: 63 trials (n = 10,441)
Induction (term): 2 trials (n = 384)
Vaginal PGE2 when compared to placebo, increased likelihood of vaginal delivery in 24 hr
Cervical ripening: 5 trials (n = 467)
Increased success in cervical ripening in vaginal PGE2 group.
Augmentation: 2 trials (n = 1,321)
Need for oxytocin augmentation reduced in vaginal PGE2 group
Cesarean sections, tachysystole: 14 trials (n = 1,259)
No difference in Cesarean section rates between vaginal PGE2 group and placebo, although rate of tachysystole with FHR changes was increased with vaginal PGE2.
Sustained release vaginal PGE2 superior to vaginal PGE2 gel in some outcomes.
Summary point: When compared to PGE2 gel, sustained release PGE2 has better outcomes in some studies. Methods and costs of drug delivery systems should be evaluated.
FHR = fetal heart rate.

This chapter addresses the indications, methods, and potential challenges of labor induction, the effect of significant complications or critical illness on the mechanisms of labor, and the effect of labor on the
compromised patient. Recommended National Institutes of Child Health and Human Development (NICHD) terminology for uterine activity and fetal surveillance is incorporated throughout the chapter. Finally, strategies for clinicians to safely care for these challenging patients are presented.


Uterine Perfusion and Labor Physiology

Oxygen delivery (DO2)—the amount of oxygen that is pumped from the left ventricle throughout the body via the arterial system—increases during pregnancy to meet increased demands. Specifically, DO2 increases secondary to increased maternal cardiac output that occurs during normal pregnancy, labor, and delivery. Oxygen consumption (VO2)—the amount of oxygen that is consumed by the body—is also increased during pregnancy to meet generalized demands, including those associated with growing fetal, placental, and maternal needs. Normal DO2 and VO2 prior to pregnancy, approximately 1,000 mL/minute and 250 mL/minute respectively, increase 20 to 40 percent during pregnancy. The increase in DO2 over non-pregnant values supplies the growing fetus and placenta, which individually consume approximately 6.6 mL/kg/minute and 3.0 mL/kg/minute of O2, respectively.4 A more thorough discussion of hemodynamic and oxygen transport concepts may be found in Chapter 4 of this text.

To accommodate the increase in maternal cardiac output in pregnancy, maternal uterine vascular beds dilate to maximum expansion, increasing perfusion and therefore gas exchange with the placenta. In fact, the internal lumen of the uterine artery doubles in size without thickening of the vessel wall.7 The expansion provides a dilated vasculature that accommodates larger volumes of blood and oxygen to the uterus and further to the placental membrane barrier. To fill the expanded vasculature, uteroplacental blood flow increases during pregnancy from a baseline volume of less than 50 mL/minute to 750 to 1000 mL/minute at term.7 It is important to note, however, that despite the increase in volume of blood flow, the uterine arteries lose auto-regulation capability during pregnancy, which may limit the maintenance of maternal blood pressure during periods of diminished flow. Since uterine blood flow is dependent upon uterine perfusion, the quantity of uterine blood flow dictates the quantity of oxygen delivered to the fetus.8 Normal maternal cardiac output and blood pressure are therefore vital for the maintenance of uterine perfusion, placental blood flow and fetal oxygenation. To maintain constant oxygen delivery during periods of decreased uterine perfusion pressures (e.g., post epidural anesthesia with vasodilation of maternal vasculature), the fetus is able to increase the oxygen extraction. However, the ability for a fetus to accomplish this feat assumes the fetus is at term, healthy, and that the uterine perfusion (maternal cardiac output) is at maximum volume prior to the decrease.8 When these conditions cannot be met in pregnancies of women with reduced cardiac output or decreased DO2, the fetus is less likely to tolerate episodes of reduced blood flow and is at a greater risk for deterioration and compromise.


Labor

Once labor begins, maternal, fetal and placental demands for oxygen dramatically increase, not only from the physical “work” of labor but also from catecholamine release related to maternal pain, anxiety and other psychosocial factors. Maternal VO2 increases approximately 86 percent (between 35 and 140 percent) during the course of labor compared to pre-labor values.4 In patients without anesthesia or analgesia, second-stage VO2 may elevate 200 to 300 percent over third trimester values. Therefore, for patients with marginal oxygen delivery, the use of effective analgesia and anesthesia during labor and delivery is essential.

Labor is defined as progressive maternal cervical effacement and dilation associated with intermittent regular uterine contractions. The establishment of progressive cervical dilation from repetitive uterine contractions relies in part on the effectiveness of intermittent pressure transferred to the fetal presenting part that is applied to the maternal cervix. The uterine myometrium produces this pressure by coordinated shortening and relaxing of muscle fibers to thin the lower uterine segment and dilate the cervix. This synchronized “work” of the uterus is dependent upon multiple maternal and fetal physiologic factors, some of which are yet to be realized. Effective myometrial activity is dependent upon adequate calcium stores, functioning calcium channels, normal uterine perfusion pressures, normal pH balance, absence of metabolic acidosis, absence of over-stretched muscle fibers, adequate glycogen stores, the availability of oxygen to maintain aerobic metabolism, and similar physiologic steady states.9,10 Additionally, the movement of calcium through channels may be further dependent on maternal lipid concentrations. An elevated concentration of serum lipids may be a factor in the increased incidence of dysfunctional labor reported in obese women.9

Each uterine contraction during labor expresses 300 to 500 mL of blood from the uterine vessels into the maternal systemic circulation.11 This transient increase in blood volume slightly decreases the maternal heart
rate; increases mean arterial pressure, central venous pressure, pulmonary artery pressures, and left ventricular filling pressures; and increases cardiac output by approximately 20 to 30 percent.12,13 These changes may significantly alter maternal cardiovascular profiles during contractions; thus, assessment and measurement of non-invasive and, if utilized, invasive hemodynamic and pulmonary parameters should be performed between contractions when the uterus is at rest.








Table 12.3 Maternal Conditions that Negatively Affect Myometrial Function








  • Decreased pH

    • From maternal systemic acidosis
    • From decreased perfusion (causes localized acidosis due to inadequate “wash out” of hydrogen ions [H+] between contractions)

  • Arterial carbon dioxide (CO2) less than 20 mmHg (due to hyperventilation)
  • Decreased cardiac output
  • Decreased mixed venous oxygen saturation (SvO2)
  • Hypotension (decreased mean arterial pressure)
  • Hypothermia
  • Metabolic acidosis
  • Hypocalcemia (rare, extremely low ionized calcium [Ca+])
  • Maternal medications

    • Examples: Calcium channel blockers, epinephrine, halothane (and other general anesthesia agents)
Arakawa, T. K., Mlynarczyk, M., Kaushal, K. M., Zhang, L., & Ducsay, C. A. (2004). Long-term hypoxia alters calcium regulation in near-term ovine myometrium. Biology of Reproduction, 71(1), 156–162.
Bursztyn, L., Eytan, O., Jaffa, A. J., & Elad, D. (2007). Mathematical model of excitation-contraction in a uterine smooth muscle cell. American Journal of Cell Physiology, 292, C1816–C1829; Bursztyn, L., Eytan, O., Jaffa, A. J., & Elad, D. (2007). Modeling myometrial smooth muscle contraction. Annals of the New York Academy of Sciences, 1101, 110–138.
Monir-Bishty, E., Pierce, S. J., Kupittayanant, S., Shmygol, A., & Wray, S. (2003). The effects of metabolic inhibition on intracellular calcium and contractility of human myometrium. BJOG, 110(12), 1050–1056.
Quenby, S., Pierce, S. J., Brigham, S., & Wray, S. (2004). Dysfunctional labor and myometrial lactic acidosis. Obstetrics and Gynecology, 103(4), 718–723.
Wray, S. (2007). Insights into the uterus. Experimental Physiology, 92, 621–631.


The Effect of Maternal Compromise on Labor

Oxygen transport and maternal pH status have been shown to affect uterine activity associated with both spontaneous and induced labor. Acute hypoxemia and/or disruption of maternal oxygen transport below a critical threshold can lead to uterine contractions, progressive cervical dilation, and delivery of the fetus at any gestational age.11 In contrast, chronic hypoxemia in some situations may work in an opposite manner to down-regulate precursors responsible for uterine contractions.9 This may help explain why a number of critically ill pregnant women continue their pregnancies for several days and/or weeks prior to the onset of labor, whereas other women exhibit uterine contractions around the time they become physiologically unstable. It is important to note that there are critical levels of maternal hypoxemia beyond which a pregnancy cannot be successfully maintained. The end result may include fetal death, spontaneous uterine expulsion of the pregnancy, or both.

Quenby and colleagues studied the effect of myometrial pH and lactate levels both in vitro and in vivo to determine their effects on uterine contractions.10 The researchers hypothesized that during a contraction the myometrium may become locally hypoxic from the loss of oxygenated vascular blood that is “squeezed” from the uterine vessels. Consequently, if the time between contractions does not permit re-establishment of vascular flow, the smooth muscle is unable to maintain aerobic metabolism; subsequently, pH values decrease and lactate levels increase. The group further found that when myometrial tissue had a low pH it was more likely to be associated with ineffective contractions compared to myometrium with a normal pH.10 From these observations, Quenby and colleagues speculated that dysfunctional labor in both critically ill and normal women may be the result of either inadequate uterine rest or tachysystole.10 It is also important to note from the same study that myometrial pH had an almost identical effect on spontaneous labor contractions versus induced labor contractions. Conditions common in patients with significant complications or critical illness that are known to negatively affect uterine activity are listed in Table 12-3.


The Effect of Labor on Compromised Patients

Once a woman has been identified as a candidate for induction of labor, further analysis of her ability to tolerate labor should be considered and specific plans made for labor management, delivery, and postpartum care. The same extensive cardiopulmonary alterations of pregnancy, labor, and birth that normal pregnant women experience and generally tolerate without problems, may have deleterious effects on patients who have complications prior to the process. Patients who are at risk for oxygen transport deterioration will be maximally challenged during the second
stage of labor and immediately postpartum—two instances that produce the most dramatic changes in fluid shifts, intra-cardiac pressures, cardiac output, oxygen demand, and pulmonary capillary permeability. These normal changes of pregnancy make the critically ill parturient and her fetus more vulnerable to decreases in maternal cardiac output and oxygen delivery.14

Induction of labor to achieve a vaginal delivery is a goal for many pregnant women with significant complications or critical illness. Vaginal delivery requires less oxygen and metabolic demand when compared to Cesarean delivery and carries a lower risk for pulmonary embolism and surgical site infection. Additionally, more blood may be lost during Cesarean versus vaginal delivery, thereby decreasing the patient’s oxygen carrying capacity and increasing her risk for inadequate DO2

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

May 22, 2016 | Posted by in OBSTETRICS | Comments Off on Induction of Labor

Full access? Get Clinical Tree

Get Clinical Tree app for offline access